Evidence map›Paper›PMID 32875542›Full record

ArticleJournal of nephrology2021

Acute pyelonephritis in children and the risk of end-stage kidney disease.

Oren Pleniceanu, Gilad Twig, Dorit Tzur, Gilad Sherman, Arnon Afek, Tomer Erlich, Lital Keinan-Boker, Karl Skorecki, Asaf Vivante, Ronit Calderon-Margalit

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Genetic determinants of renal scarring in children with febrile UTI.Pediatric nephrology (Berlin, Germany) · 2024
    Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Oren PleniceanuIsrael Defense Forces, Medical Corps, Ramat Gan, Israel.ORCID http://orcid.org/0000-0003-0537-4469
Gilad TwigIsrael Defense Forces, Medical Corps, Ramat Gan, Israel.
Dorit TzurIsrael Defense Forces, Medical Corps, Ramat Gan, Israel.
Gilad ShermanSackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Arnon AfekSackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Tomer ErlichIsrael Defense Forces, Medical Corps, Ramat Gan, Israel.
Lital Keinan-BokerIsrael Center for Disease Control, Ministry of Health, Ramat Gan, Israel.
Karl SkoreckiDepartment of Nephrology, Rambam Health Care Campus and the Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Asaf Vivante *Talpiot Medical Leadership Program, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel. asafvivante@gmail.com.
Ronit Calderon-Margalit *Hadassah-Hebrew University Braun School of Public Health, Jerusalem, Israel. ronitcm@gmail.com.
Tel Aviv University · ILBar-Ilan University · ILHebrew University of Jerusalem · ILIsrael Defense Forces Medical Corps · ILIsrael Ministry of Health · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPyelonephritis is the most common serious bacterial infection during childhood. The long-term importance of kidney scarring is unclear.

objectiveTo assess the risk of end-stage kidney disease (ESKD) in adolescents and young adults with history of pyelonephritis. STUDY

designA nationwide, population-based, historical cohort study, including 1,509,902 persons (62% male) examined for military service between 1967 and 1997. Participants with a history of pyelonephritis were sub-grouped according to presence of kidney scarring and baseline kidney function. Data were linked to the Israeli ESKD registry to identify incident ESKD cases. Cox proportional hazards models were used to estimate the hazard ratio (HR) of treated ESKD (dialysis or kidney transplant).

resultsPyelonephritis was diagnosed in 6979 participants (0.46%). 6479 had normal kidney function and no evidence of kidney scarring, 400 had normal kidney function with evidence of scarring, and 100 demonstrated reduced baseline kidney function. Treated ESKD developed in 2352 individuals (0.2%) without history of pyelonephritis, 58 individuals (0.9%) with normal kidney function, history of pyelonephritis and no kidney scarring, 14 individuals (3.5%) with normal kidney function, history of pyelonephritis and kidney scarring, and 23 individuals (23.0%) with history of pyelonephritis and reduced baseline kidney function, yielding HR of 3.3, 34.8 and 43.2, respectively, controlling for age, gender, paternal origin, enrollment year, body mass index, and blood pressure, and accounting for death as a competing risk.

conclusionHistory of pyelonephritis was associated with significantly increased risk of treated ESKD, particularly when associated with kidney scarring or reduced baseline kidney function.

Indexed as

Kidney Failure, ChronicPyelonephritisAdolescentChildCohort StudiesFemaleHumansMaleProportional Hazards ModelsRenal DialysisChronic kidney diseaseClinical epidemiologyDialysisEnd-stage kidney diseaseKidney transplantationPyelonephritis

Identifiers

PMID32875542
OpenAlexW3081909570

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.